Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine - PubMed
5 hours ago
- #COPD
- #biologics
- #precision medicine
- COPD is the third leading cause of death worldwide with limited efficacy from conventional bronchodilator therapies.
- 2024-2026 marks a historic shift with FDA approval of three novel agents, moving towards precision medicine.
- New therapies include dual phosphodiesterase-3/4 inhibitors, biologics targeting type 2 inflammation, and emerging technologies like gene editing.
- The 'treatable traits' framework emphasizes targeting specific modifiable pathobiological characteristics over categorical diagnosis.
- Evidence-based guidance is provided for treatment selection using biomarkers, considering pharmacoeconomics and implementation challenges.
- COPD therapeutics are advancing towards disease modification with biologics, small molecules, and new technologies.